Cerus' blood-safety system meets main goal in late-stage trial

3

Nov 2 (Reuters) – Cerus Corp said on Monday a late-stage study showed that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)